Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 SCHELLING CERTIFICATION PURSUANT TO SEC 906 - Acer Therapeutics Inc. | acer-ex321_8.htm |
| 10-K - 10-K - Acer Therapeutics Inc. | acer-10k_20191231.htm |
| EX-32.2 - EX-32.2 PALMIN CERTIFICATION PURSUANT TO SEC 906 - Acer Therapeutics Inc. | acer-ex322_12.htm |
| EX-31.2 - EX-31.2 PALMIN CERTIFICATION PURSUANT TO SEC 302 - Acer Therapeutics Inc. | acer-ex312_10.htm |
| EX-31.1 - EX-31.1 SCHELLING CERTIFICATION PURSUANT TO SEC 302 - Acer Therapeutics Inc. | acer-ex311_6.htm |
| EX-23.2 - EX-23.2 - Acer Therapeutics Inc. | acer-ex232_411.htm |
| EX-10.27 - EX-10.27 - Acer Therapeutics Inc. | acer-ex1027_794.htm |
| EX-4.1 - EX-4.1 - Acer Therapeutics Inc. | acer-ex41_179.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Acer Therapeutics Inc.
Newton, Massachusetts
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-228319) and Form S-8 (Nos. 333-221566, 333-224942 and 333-230133) of Acer Therapeutics Inc. of our report dated March 18, 2020, relating to the consolidated financial statements, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Boston, Massachusetts
March 18, 2020